N/A N=257 Down Syndrome Metabolic Health Study
Down Syndrome · Trisomy 21
Primary: Non-HDL Cholesterol — 128; 107 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Down Syndrome · Obstructive Sleep Apnea Syndrome
Primary: Change in Epworth Sleepiness Scale From Baseline to End of Study — -1; -0.5; 1 units on a scale
N/A N=6 Gait in Children With Down Syndrome While Wearing Orthoses
Down Syndrome
Primary: Step Width — 10.4 cm
N/A N=18 Predictors of Speech Ability in Down Syndrome
Speech Intelligibility Intervention in Down Syndrome
Primary: Speech Intelligibility — 3.59 score on a scale
N/A N=230 An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You
Down Syndrome
Primary: Number of Participants With Indicated Evaluations That Were Completed or Recommended by the PCP — 69; 79; 36; 31 participants — p=0.018
N/A N=60 Blood Flow Regulation in Individuals With Down Syndrome - Training Study
Down Syndrome
Primary: Change From Baseline Work Capacity at 13 Weeks — -1.20; -0.18 change in ml/kg/min — p=0.660
N/A N=758 Developing a Down Syndrome Health Instrument
Down Syndrome · Health, Subjective
Primary: Number of Completed Surveys for Validation Analysis — 0; 0; 542 Participants
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 2 N=23 A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Down Syndrome
Primary: Incidence of Adverse Events (TEAEs) — 5; 2; 0 participants
N/A N=8 Balance Bike Training in Down Syndrome
Down Syndrome · Postural Balance
Primary: Pediatric Balance Scale (PBS) Mean Group Score — 48.43; 49.43 score on a scale — p=<0.05
N/A N=81 The Promotion of Physical Activity for the Prevention of Alzheimer's Disease in Adults With Down Syndrome
Down Syndrome · Alzheimer Disease
Primary: Minutes of Moderate to Vigorous Physical Activity (MVPA) Per Day — 13.8; 17.9; 15.6; 21.8 min of MVPA/day
Phase 2 N=160 Down Syndrome Memantine Follow-up Study
Down Syndrome · Intellectual Disability
Primary: Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall — 3.3; 3.49 score on a…
N/A N=42 Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)
Down Syndrome · Obstructive Sleep Apnea
Primary: Number of Participants Who Completed Interviews Regarding Positive Airway Pressure (PAP) Acceptability — 20; 21 Participants
N/A N=84 Assessing Malleability of Spatial Abilities in Down Syndrome
Down Syndrome
Primary: Change in Mental Rotation Ability at 8 Weeks — 0.0; -0.6; .82 Amount of Change in Number Correct Items — p==.066
N/A N=30 Spectacles for Patients With Down Syndrome
Vision, Low
Primary: Adapted Visual Acuity — 0.256; 0.440; 0.356; 0.284 logMAR — p=0.341
Phase 1 N=16 Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
Down Syndrome
Primary: Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value — 632.3; 335.4; 162.8; 751.5 AU/mL (AU: Arbitrary Unit)
N/A N=20 Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome
Down Syndrome · Physical Inactivity
Primary: Attendance — 21.7 Number of Classes Attended
N/A N=42 A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea
Sleep Apnea, Obstructive · Down Syndrome
Primary: Serious Adverse Events — 7 participants
Phase 4 N=39 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Down Syndrome
Primary: Changes in Neuropsychological Measures From Baseline to End of Study — -0.22; -0.84; 0.56; 0 units on a scale — p=0.403
Phase 2 N=47 Tofacitinib for Immune Skin Conditions in Down Syndrome
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Phase 4 N=4 Fluoxetine Treatment of Depression in Down Syndrome
Down Syndrome · Depression
Primary: Proportion of Participants Who Responded to Treatment at 16 Weeks According to Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or…
Phase 1 N=12 Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Down Syndrome
Primary: Safety Measured by Adverse Events — 0; 0 Participants
Phase 2 N=109 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Down Syndrome · Amyloid Beta-protein
Primary: Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome…
N/A N=20 GameSquad for Adults With Down Syndrome
Down Syndrome · Physical Inactivity
Primary: Minutes of Gameplay Per Week — 100.32 minutes/week
N/A N=17 Use of Partial Body Weight Support Play Environment to Encourage Mobility and Exploration in Infants With Down Syndrome
Down Syndrome · Trisomy 21
Primary: Change in Movement Counts Per 15 Seconds From Baseline (Week 1) to Mid Study (Week 5) — -34.46; -88.62 movement counts per 15 seconds
Phase 3 N=175 Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
Down Syndrome
Primary: GMDS (Griffiths Mental Development Scale) — 51.96; 51.27; 51.66; 51.67 developpement quotient
Phase 2 N=129 Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
Down Syndrome
Primary: Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form…
Phase 2 N=8 Rivastigmine Study in Adolescents With Down Syndrome
Down Syndrome
Primary: Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form) — -1.7; 2.0 units on a scale
Phase 2 N=7 Nicotine Treatment of Cognitive Decline in Down Syndrome
Down Syndrome · Mild Cognitive Impairment
Primary: Tolerability of Nicotine Intervention — 1; 3 Participants
N/A N=22 Treadmill Training and Orthotic Use in Infants With Down Syndrome
Down Syndrome
Primary: Pattern of Gross Motor Development — 28.2; 28.3 months